Combined effect of atovaquone and pyrrolidine dithiocarbamate in the treatment of acute murine toxoplasmosis

Chemotherapy

Volumn 50, Issue 3, 2004, Pages 155-156

  Djurkovic Djakovic O ^a   Nikolic A ^a   Bobic B ^a   Klun, I ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; AZITHROMYCIN; PYRROLIDINE DITHIOCARBAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; LETHARGY; LETTER; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REFLEX; STATISTICAL SIGNIFICANCE; SURVIVAL; TOXOPLASMA GONDII; TOXOPLASMOSIS; WEIGHT REDUCTION;

EID: 3242764491     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077891     Document Type: Letter

References (16)

1. Freerksen E, Rosenfeld M, Spannuth G: Integrated complex combinations for the treatment of opportunistic infections in AIDS. Chemotherapy 1989;35:208-220.
2. Haller L, Sossouhounto R, Coulibaly IM, Dosso M, Kone M, Adom H, Meyer UA, Betschart B, Wenk M, Haefeli WE, Lobognon LR, Porquet M, Kaboré G, Sorenson F, Reber-Liske R, Stürchler D: Isoniazid plus sulphadoxine- pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: A controlled clinical trial. Chemotherapy 1999;45:452-465.
3. Samuel R, Bettiker RL, Suh B: AIDS related opportunistic infections, going but not gone. Arch Pharm Res 2002;25:215-228.
4. Baggish AL, Hill DR: Antiparasitic agent atovaquone. Antimicrob Agents Chemother 2002;46:1163-1173.
5. McCabe RE: Antitoxoplasma chemotherapy; in Joynson DHM, Wreghitt TG (eds): Toxoplasmosis. Cambridge, Cambridge University Press, 2001, pp 319-359.
6. Camps M, Boothroyd JC: Toxoplasma gondii: Selective killing of extracellular parasites by oxidation using pyrrolidine diothiocarbamate. Exp Parasitol 2001;98:206-214.
7. Djurković-Djaković O, Nikolić T, Robert-Gangneux F, Bobić B, Nikolić A: Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis. Antimicrob Agents Chemother 1999;43:2240-2244.
8. Sibley LD, Boothroyd JC: Virulent strains of Toxoplasma gondii comprise a single clonal lineage. Nature 1992;359:82-85.
9. Reisinger EC, Kern P, Ernst M, Bock P, Flad HD, Dietrich M: Inhibition of HIV progression by dithiocarb. German DTC Study Group. Lancet 1990;335:679-682.
10. Meisner M, Schmidt J, Schywalsky M, Tschaikowsky K: Influence of pyrrolidine dithiocarbamate on the inflammatory response in macrophages and mouse endotoxin shock. Int J Immunopharmacol 2000;22:83-90.
11. Gaudernak E, Seipelt J, Triendl A, Grassauer A, Kuechler E: Antiviral effects of pyrrolidine dithiocarbamate on human rhinoviruses. J Virol 2002;76:6004-6015.
12. Uchide N, Ohyama K: Antiviral function of pyrrolidine dithiocarbamate against influenza virus: The inhibition of viral gene replication and transcription. J Antimicrob Chemother 2003;52:8-10.
13. Pearson PA, Piracha AR, Sen HA, Jaffe GJ: Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology 1999;106:148-153.
14. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, Roque C, Rajicic N, McAuliffe V, Morlat P, Jayaweera DT, Vilde J-L, Luft BJ: Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis 2002;34:1243-1250.
15. Dawis MA, Bottone EJ, Vlachos A, Burroughs MH: Unsuspected Toxoplasma gondii empyema in a bone marrow transplant recipient. Clin Infect Dis 2002;34:e37-e39.
16. McFadden DC, Camps M, Boothroyd J: Resistance as a tool in the study of old and new targets in Toxoplasma. Drug Resist Updat 2001;4:1-6.